J Korean Med Assoc.  2012 May;55(5):484-490. 10.5124/jkma.2012.55.5.484.

The contraindication of comedication drugs and drug utilization review

• Park JY
• Park KW

• KMID: 2064805
• DOI: http://doi.org/10.5124/jkma.2012.55.5.484

Abstract

A drug interaction can be defined as an interaction between a drug and other drugs that prevent the drug from performing as expected. These processes may include alterations in the pharmacokinetics of the drug, such as modulations in the absorption, distribution, metabolism, and elimination (ADME) of a drug. Alternatively, drug interactions may be the result of the pharmacodynamic characteristics of the drug: the concomitant medication of a receptor antagonist and an agonist for the same receptor. The following interaction may increase or decrease the effectiveness of the drugs or the adverse drug reactions of the drugs. The possibilities of drug interactions should increase as the number of drugs being taken increases in patients. Therefore, patients taking several drugs simultaneously are at the greatest risk for interactions. Drug interactions can contribute to the increasing cost of healthcare because of the costs of medical care that are required to treat problems caused by changes in effectiveness or adverse drug reactions. The drug utilization review (DUR) system has been defined as a structured, ongoing initiative that interprets patterns of drug usage in relation to predetermined criteria and attempts to prevent or minimize inappropriate prescribing. The primary objectives of DUR are to improve the quality of health care for healthcare members and to assist in containing health care costs. In order to achieve these goals, prescription claims must be reviewed both prospectively and retrospectively. The DUR system supplies information to prohibit co-dispensing of contraindicated drugs which increases the risk of drug interactions properly to all the healthcare professionals participating in the care of the patients. In this article, we suggest the importance of DUR in relation to the contraindication of co-medication drugs.

Keyword

Drug interactions; Contraindication of comedication drugs; Drug utilization review

MeSH Terms

Absorption
Delivery of Health Care
Diphtheria Toxoid
Drug Interactions
Drug Toxicity
Drug Utilization
Drug Utilization Review
Equipment and Supplies
Haemophilus Vaccines
Health Care Costs
Humans
Inappropriate Prescribing
Prescriptions
Quality of Health Care
Diphtheria Toxoid
Haemophilus Vaccines

Reference

1. D'Arcy PF. Adverse reactions and interactions with herbal medicines. Part 1. Adverse reactions. Adverse Drug React Toxicol Rev. 1991. 10:189–208.

2. Ingelman-Sundberg M. Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J Intern Med. 2001. 250:186–200.

3. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998. 279:1200–1205.

4. Marroum PJ, Uppoor RS, Parmelee T, Ajayi F, Burnett A, Yuan R, Svadjian R, Lesko LJ, Balian JD. In vivo drug-drug interaction studies: a survey of all new molecular entities approved from 1987 to 1997. Clin Pharmacol Ther. 2000. 68:280–285.

5. Gallicano K, Drusano G. Piscitelli SC, Rodvold K, editors. Introduction to drug interactions. Drug interactions in infectious diseases. 2005. 2nd ed. Totowa: Humana Press Inc;1–12.

6. Drug development and drug interactions: table of substrates, inhibitors and inducers [Internet]. U.S. Food and Drug Administration. 2011. cited 2012 Apr 17. Silver Spring: U.S. Food and Drug Administration;Avaiable from: http://www.Fda.Gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.Htm#4.

7. Notification for co-dispensing of contraindicated drugs [Internet]. 2010. cited 2012 Apr 30. Cheongwon: Korea Food and Drug Administration;Available from: http://kfda.go.kr/index.kfda?mid=70&cd=213.

8. Oliver JJ, Dear JW, Webb DJ. Clinical potential of combined organic nitrate and phosphodiesterase type 5 inhibitor in treatment-resistant hypertension. Hypertension. 2010. 56:62–67.

9. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006. 80:565–581.

10. Ucar M, Mjorndal T, Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf. 2000. 22:441–457.

11. Omnibus Budget Reconciliation Act of 1990 (OBRA 90), Pub. L. 101-508, 104 Stat. 1388. 1990. 11. 05.

12. Hsu A, Granneman GR, Bertz RJ. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet. 1998. 35:275–291.

13. Croxtall JD, Perry CM. Lopinavir/Ritonavir: a review of its use in the management of HIV-1 infection. Drugs. 2010. 70:1885–1915.

14. World Health Organization Expert Committee on the Selection of Essential Drugs. The selection of essential drugs. Report series no. 615. 1977. Geneva: World Health Organization.

15. Soumerai SB, Lipton HL. Computer-based drug-utilization review-risk, benefit, or boondoggle? N Engl J Med. 1995. 332:1641–1645.

16. Park BJ. Drug utilization review. J Pharmacoepidemiol Risk Manag. 2008. 1:13–19.

17. Park JY. DUR progress in the implementation and ways to expand nationwide. HIRA Policy Trend. 2010. 4:23–28.

18. Choi NK, Park BJ. Strategy for establishing an effective Korean drug utilization review system. J Korean Med Assoc. 2010. 53:1130–1138.